SAXSdb — 8q6h

▼

1. Protein Identity and Related Structures Protein Identity & Related Structures

Phosphatidylinositol 4-kinase beta

Homo sapiens

State in the Current Structure

Assembly	Oligomeric State	Construct	Mutations and Modifications	Ligands, Ions and Associated Components	Method and Experimental Conditions	Structure Quality
1	Insufficient information Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count	Chain A； UniProt 531–828	Mutation：R409Q,R412Q	MG MAGNESIUM ION × 1 KI7 3-(3-fluorosulfonyloxy-4-methoxy-phenyl)-7-[(4-fluorosulfonyloxyphenyl)methylamino]-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Sodium Formate	Resolution 1.94 Å R-free 0.237

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB	Difference from Current Entry 8Q6H	Assembly / Oligomeric State	Construct	Mutations and Modifications	Ligands, Ions and Non-polymers	Method and Experimental Conditions	Structure Quality
2N73 Solution structure of the ACBD3:PI4KB complex Deposited 2015-09-02	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics	Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric	Chain B 5–80（76 aa） Fragment：UNP residues 5-80	Not recorded	No recorded non-water small molecule	SOLUTION NMR NMR measurement conditions pH 6.5；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure ambient NMR sample composition 0.47 mM [U-13C; U-15N] protein_1, 0.47 mM [U-13C; U-15N] protein_2, 90% H2O/10% D2O \| 90% H2O/10% D2O	Resolution not provided
5LX2 Lt 14-3-3 in complex with PI4KIIIB peptide Deposited 2016-09-19	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric	Chain B 304–309（6 aa） Fragment：UNP residues 304-309	Non-standard monomer：Yes (specific site not provided by mmCIF)	No recorded non-water small molecule	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；MES, PEG 8000, ethylene glycol	Resolution 2.58 Å R-free 0.263
8Q6F HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 4) Deposited 2023-08-11	Different ligand/ion Different structure-quality metrics	Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric	Chain A 531–828（298 aa）	Mutation：R409Q,R412Q	KHR 3-(3-fluorosulfonyloxy-4-methoxy-phenyl)-2,5-dimethyl-7-(pyridin-4-ylmethylamino)pyrazolo[1,5-a]pyrimidine × 1 MG MAGNESIUM ION × 1 EDO 1,2-ETHANEDIOL × 7 GOL GLYCEROL × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Sodium Formate	Resolution 1.51 Å R-free 0.224
8Q6G HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 8) Deposited 2023-08-11	Different ligand/ion Different structure-quality metrics	Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric	Chain A 531–828（298 aa）	Mutation：R409Q,R412Q	KIH 3-(3,4-dimethoxyphenyl)-7-[(4-fluorosulfonyloxyphenyl)methylamino]-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine × 1 MG MAGNESIUM ION × 1 EDO 1,2-ETHANEDIOL × 3	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Sodium Formate	Resolution 1.54 Å R-free 0.221

4 other PDB entries and 4 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence

UniProt name	A0A0B4J1S8_HUMAN
Isoform	—
PDB entities	1
Chains and sequence ranges	Author chain A； PDBConstruct 127–424； UniProt 531–828

Phosphatidylinositol 4-kinase beta

Homo sapiens

UniProt Q9UBF8

State in the Current Structure

Assembly	Oligomeric State	Construct	Mutations and Modifications	Ligands, Ions and Associated Components	Method and Experimental Conditions	Structure Quality
1	Insufficient information Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count	Chain A； UniProt 291–415	Mutation：R409Q,R412Q	MG MAGNESIUM ION × 1 KI7 3-(3-fluorosulfonyloxy-4-methoxy-phenyl)-7-[(4-fluorosulfonyloxyphenyl)methylamino]-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Sodium Formate	Resolution 1.94 Å R-free 0.237

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB	Difference from Current Entry 8Q6H	Assembly / Oligomeric State	Construct	Mutations and Modifications	Ligands, Ions and Non-polymers	Method and Experimental Conditions	Structure Quality
4D0L Phosphatidylinositol 4-kinase III beta-PIK93 in a complex with Rab11a- GTP gammaS Deposited 2014-04-29	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric	Chain A 121–407（287 aa） Fragment：RESIDUES 121-407,508-784 Chain A 508–784（277 aa） Fragment：RESIDUES 121-407,508-784	Mutation：YES Mutation：YES	093 N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1	X-RAY DIFFRACTION X-ray crystallization conditions pH 5.6；15% (W/V) PEG 4000, 0.1 M NA CITRATE PH 5.6, AND 0.2 M AMMONIUM ACETATE	Resolution 2.94 Å R-free 0.259
4D0L Phosphatidylinositol 4-kinase III beta-PIK93 in a complex with Rab11a- GTP gammaS Deposited 2014-04-29	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric	Chain C 121–407（287 aa） Fragment：RESIDUES 121-407,508-784 Chain C 508–784（277 aa） Fragment：RESIDUES 121-407,508-784	Mutation：YES Mutation：YES	093 N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1	X-RAY DIFFRACTION X-ray crystallization conditions pH 5.6；15% (W/V) PEG 4000, 0.1 M NA CITRATE PH 5.6, AND 0.2 M AMMONIUM ACETATE	Resolution 2.94 Å R-free 0.259
4D0L Phosphatidylinositol 4-kinase III beta-PIK93 in a complex with Rab11a- GTP gammaS Deposited 2014-04-29	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric	Chain E 121–407（287 aa） Fragment：RESIDUES 121-407,508-784 Chain E 508–784（277 aa） Fragment：RESIDUES 121-407,508-784	Mutation：YES Mutation：YES	093 N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1	X-RAY DIFFRACTION X-ray crystallization conditions pH 5.6；15% (W/V) PEG 4000, 0.1 M NA CITRATE PH 5.6, AND 0.2 M AMMONIUM ACETATE	Resolution 2.94 Å R-free 0.259
4D0M Phosphatidylinositol 4-kinase III beta in a complex with Rab11a-GTP- gamma-S and the Rab-binding domain of FIP3 Deposited 2014-04-29	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein heterocomplex Heteromer；Protein × 12 PDB declaration: dodecameric	Chain A 121–303（183 aa） Chain A 319–421（103 aa） Chain A 522–799（278 aa） Chain C 121–303（183 aa） Chain C 319–421（103 aa） Chain C 522–799（278 aa） Chain O 121–303（183 aa） Chain O 319–421（103 aa） Chain O 522–799（278 aa） Chain S 121–303（183 aa） Chain S 319–421（103 aa） Chain S 522–799（278 aa）	Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES	093 N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE × 4 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 4 MG MAGNESIUM ION × 4	X-RAY DIFFRACTION X-ray crystallization conditions 16% PEG 6K, 0.01 M NA CITRATE	Resolution 6.00 Å R-free 0.359
4D0M Phosphatidylinositol 4-kinase III beta in a complex with Rab11a-GTP- gamma-S and the Rab-binding domain of FIP3 Deposited 2014-04-29	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 2 Protein heterocomplex Heteromer；Protein × 12 PDB declaration: dodecameric	Chain G 121–303（183 aa） Chain G 319–421（103 aa） Chain G 522–799（278 aa） Chain I 121–303（183 aa） Chain I 319–421（103 aa） Chain I 522–799（278 aa） Chain M 121–303（183 aa） Chain M 319–421（103 aa） Chain M 522–799（278 aa） Chain Q 121–303（183 aa） Chain Q 319–421（103 aa） Chain Q 522–799（278 aa）	Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES	093 N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE × 4 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 4 MG MAGNESIUM ION × 4	X-RAY DIFFRACTION X-ray crystallization conditions 16% PEG 6K, 0.01 M NA CITRATE	Resolution 6.00 Å R-free 0.359
4D0M Phosphatidylinositol 4-kinase III beta in a complex with Rab11a-GTP- gamma-S and the Rab-binding domain of FIP3 Deposited 2014-04-29	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 3 Protein heterocomplex Heteromer；Protein × 12 PDB declaration: dodecameric	Chain W 121–303（183 aa） Chain W 319–421（103 aa） Chain W 522–799（278 aa） Chain Y 121–303（183 aa） Chain Y 319–421（103 aa） Chain Y 522–799（278 aa） Chain c 121–303（183 aa） Chain c 319–421（103 aa） Chain c 522–799（278 aa） Chain g 121–303（183 aa） Chain g 319–421（103 aa） Chain g 522–799（278 aa）	Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES	093 N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE × 4 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 4 MG MAGNESIUM ION × 4	X-RAY DIFFRACTION X-ray crystallization conditions 16% PEG 6K, 0.01 M NA CITRATE	Resolution 6.00 Å R-free 0.359
4WAE Phosphatidylinositol 4-kinase III beta crystallized with ATP Deposited 2014-08-29	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric	Chain A 128–422（295 aa） Fragment：UNP residues 130-422, UNP residues 523-799 Chain A 523–799（277 aa） Fragment：UNP residues 130-422, UNP residues 523-799	Not recorded	ATP ADENOSINE-5'-TRIPHOSPHATE × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；10% w/v PEG 4000, 20% v/v glycerol 0.1 M MOPS/HEPES-Na pH 7.5	Resolution 3.32 Å R-free 0.244
4WAG Phosphatidylinositol 4-kinase III beta crystallized with MI103 inhibitor Deposited 2014-08-29	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric	Chain A 128–422（295 aa） Fragment：UNP residues 128-422, UNP residues 523-799 Chain A 523–799（277 aa） Fragment：UNP residues 128-422, UNP residues 523-799	Not recorded	3K7 6-chloro-3-(3,4-dimethoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-amine × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；10% w/v PEG 4000, 20% v/v glycerol 0.1 M MOPS/HEPES-Na pH 7.5	Resolution 3.41 Å R-free 0.251
5C46 Crystal structure of an engineered construct of phosphatidylinositol 4 kinase III beta in complex with GTP gamma S loaded Rab11 Deposited 2015-06-17	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric	Chain E 121–248（128 aa） Chain E 288–407（120 aa） Chain E 508–784（277 aa）	Mutation：S294A Mutation：S294A Mutation：S294A	SO4 SULFATE ION × 2 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.6；290 K；PEG-4000, sodium citrate, ammonium sulfate, glycerol	Resolution 2.65 Å R-free 0.246
5C4G Crystal structure of an engineered construct of phosphatidylinositol 4 kinase III beta with the inhibitor BQR695 in complex with GDP loaded Rab11 Deposited 2015-06-18	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric	Chain E 121–248（128 aa） Chain E 288–407（120 aa） Chain E 508–784（277 aa）	Mutation：S294A Mutation：S294A Mutation：S294A	MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 SO4 SULFATE ION × 2 BQR N~2~-[7-(3,4-dimethoxyphenyl)quinoxalin-2-yl]-N-methylglycinamide × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.6；290 K；PEG-4000, sodium citrate, ammonium sulfate, glycerol	Resolution 3.20 Å R-free 0.287
5EUQ Crystal structure of an engineered construct of phosphatidylinositol 4 kinase III beta with a potent and selective inhibitor in complex with GDP loaded Rab11 Deposited 2015-11-19	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric	Chain E 121–248（128 aa） Chain E 523–799（277 aa）	Mutation：S294A Mutation：S294A	GDP GUANOSINE-5'-DIPHOSPHATE × 1 SO4 SULFATE ION × 2 5S8 ~{N}-[5-[3-[[(4-hydroxyphenyl)amino]-bis(oxidanyl)-$l^{4}-sulfanyl]-4-methoxy-phenyl]-4-methyl-1,3-thiazol-2-yl]cyclopentanecarboxamide × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION；pH 5.6；290 K；PEG-4000, sodium citrate, ammonium sulfate, glycerol	Resolution 3.20 Å R-free 0.266
5FBL PI4KB in complex with Rab11 and the MI356 Inhibitor Deposited 2015-12-14	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric	Chain A 128–422（295 aa） Fragment：UNP Residues 128-422, 523-799 Chain A 523–799（277 aa） Fragment：UNP Residues 128-422, 523-799	Not recorded	5W9 ~{N}-[2-[[6-chloranyl-3-(4-methoxy-3-morpholin-4-ylsulfonyl-phenyl)-2-methyl-imidazo[1,2-b]pyridazin-8-yl]amino]ethyl]ethanamide × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；1M Lithium chloride, 0.1M Citric acid pH=5, 10% (w/v) PEG 6000	Resolution 3.37 Å R-free 0.269
5FBQ PI4KB in complex with Rab11 and the MI358 Inhibitor Deposited 2015-12-14	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric	Chain A 128–422（295 aa） Fragment：UNP Residues 128-422, 523-799 Chain A 523–799（277 aa） Fragment：UNP Residues 128-422, 523-799	Not recorded	5W6 ~{N}-[2-[[6-chloranyl-3-[3-[4-(hydroxymethyl)piperidin-1-yl]sulfonyl-4-methoxy-phenyl]-2-methyl-imidazo[1,2-b]pyridazin-8-yl]amino]ethyl]ethanamide × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；0.2M magnesium chloride, 0.1M Tris PH=7, 10% (w/v) PEG 8000	Resolution 3.79 Å R-free 0.302
5FBR PI4KB in complex with Rab11 and the MI359 Inhibitor Deposited 2015-12-14	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric	Chain A 128–422（295 aa） Fragment：UNP Residues 128-422, 523-799 Chain A 523–799（277 aa） Fragment：UNP Residues 128-422, 523-799	Not recorded	5W7 ~{N}-[2-[[3-[3-[(4-azanylcyclohexyl)sulfamoyl]-4-methoxy-phenyl]-6-chloranyl-2-methyl-imidazo[1,2-b]pyridazin-8-yl]amino]ethyl]ethanamide × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；0.15M amonium sulfate, 0.1M MES pH=6, 15% PEG 4000	Resolution 3.28 Å R-free 0.264
5FBV PI4KB in complex with Rab11 and the MI364 Inhibitor Deposited 2015-12-14	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric	Chain A 128–422（295 aa） Fragment：UNP Residues 128-422, 523-799 Chain A 523–799（277 aa） Fragment：UNP Residues 128-422, 523-799	Not recorded	5W3 ~{N}-[2-[[6-chloranyl-3-[3-(2-hydroxyethylsulfamoyl)-4-methoxy-phenyl]-2-methyl-imidazo[1,2-b]pyridazin-8-yl]amino]ethy l]ethanamide × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；0.15M amonium sulfate, 0.1M MEW pH=6, 15% PEG 4000	Resolution 3.29 Å R-free 0.281
5FBW PI4KB in complex with Rab11 and the MI369 Inhibitor Deposited 2015-12-14	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric	Chain A 128–422（295 aa） Fragment：UNP Residues 128-422, 523-729,UNP Residues 128-422, 523-729 Chain A 191–467（277 aa） Fragment：UNP Residues 128-422, 523-729,UNP Residues 128-422, 523-729	Not recorded	5W8 ~{N}-[2-[[6-chloranyl-3-[4-methoxy-3-[[(2~{R})-1-oxidanylbutan-2-yl]sulfamoyl]phenyl]-2-methyl-imidazo[1,2-b]pyridazin-8-yl]amino]ethyl]ethanamide × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；0.2M ammonium sulfate, 0.1M MES pH=6.5, 20% (w/v) PEG 8000	Resolution 3.49 Å R-free 0.283
5NAS Crystal structure of human 14-3-3 zeta in complex with PI4KIIIB peptide Deposited 2017-02-28	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric	Chain C 289–297（9 aa） Fragment：UNP residues 289-297 Chain D 289–297（9 aa） Fragment：UNP residues 289-297	Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF)	No recorded non-water small molecule	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；MES, PEG, ethylene glycol	Resolution 2.08 Å R-free 0.231
6GL3 Crystal structure of human Phosphatidylinositol 4-kinase III beta (PI4KIIIbeta) in complex with ligand 44 Deposited 2018-05-22	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric	Chain A 317–428（112 aa） Chain A 532–798（267 aa）	Not recorded	EMW (3~{S})-4-(6-azanyl-1-methyl-pyrazolo[3,4-d]pyrimidin-4-yl)-~{N}-(4-methoxy-2-methyl-phenyl)-3-methyl-piperazine-1-carboxamide × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M sodium citrate, 22% (w/v) PEG3350, 10 mM Manganese(II)chloride	Resolution 2.77 Å R-free 0.333
6GL3 Crystal structure of human Phosphatidylinositol 4-kinase III beta (PI4KIIIbeta) in complex with ligand 44 Deposited 2018-05-22	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric	Chain B 317–428（112 aa） Chain B 532–798（267 aa）	Not recorded	No recorded non-water small molecule	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M sodium citrate, 22% (w/v) PEG3350, 10 mM Manganese(II)chloride	Resolution 2.77 Å R-free 0.333
8Q6F HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 4) Deposited 2023-08-11	Different ligand/ion Different structure-quality metrics	Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric	Chain A 291–415（125 aa）	Mutation：R409Q,R412Q	KHR 3-(3-fluorosulfonyloxy-4-methoxy-phenyl)-2,5-dimethyl-7-(pyridin-4-ylmethylamino)pyrazolo[1,5-a]pyrimidine × 1 MG MAGNESIUM ION × 1 EDO 1,2-ETHANEDIOL × 7 GOL GLYCEROL × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Sodium Formate	Resolution 1.51 Å R-free 0.224
8Q6G HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 8) Deposited 2023-08-11	Different ligand/ion Different structure-quality metrics	Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric	Chain A 291–415（125 aa）	Mutation：R409Q,R412Q	KIH 3-(3,4-dimethoxyphenyl)-7-[(4-fluorosulfonyloxyphenyl)methylamino]-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine × 1 MG MAGNESIUM ION × 1 EDO 1,2-ETHANEDIOL × 3	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Sodium Formate	Resolution 1.54 Å R-free 0.221
8VOF GI targeted CpPI4K inhibitor Deposited 2024-01-15	Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics	Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric	Chain A 121–407（287 aa）	Mutation：L294A,L374Y,P597Y	A1ADE methyl 2-chloro-5-(methyl{(8R)-3-[4-(methylcarbamoyl)phenyl]pyrazolo[1,5-a]pyridine-5-carbonyl}amino)benzoate × 1 SO4 SULFATE ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1	X-RAY DIFFRACTION X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；294 K；0.5M ammonium sulfate, 0.088M sodium citrate, 0.875M lithium sulfate, 2.4% glycerol, 2.5% ethylene glycol, 50mM HEPES pH 6.8	Resolution 3.00 Å R-free 0.270

17 other PDB entries and 22 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence

UniProt name	PI4KB_HUMAN
Isoform	Q9UBF8-2
PDB entities	1
Chains and sequence ranges	Author chain A； PDBConstruct 2–126； UniProt 291–415

The page prioritizes protein identity, the current assembly, associated components, oligomeric state and cross-PDB links. Chain mapping and sequence ranges are retained as data evidence. Internal IDs, import timestamps and assembly operation expressions are maintenance fields and are not shown here.

▼

2. Structure Basics 2. Structure Basics

Entry ID entry_id	8q6h
Deposition date deposition_date	2023-08-11
Structure title title	HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 11)
Keywords keywords	LIPID KINASE, TRANSFERASE-SIGNALING PROTEIN COMPLEX, COVALENT INHIBITOR., TRANSFERASE; TRANSFERASE
Experimental Method method	X-RAY DIFFRACTION

▼

3. SAXS Parameters (CRYSOL theoretical calculation) 3. SAXS Parameters (CRYSOL)

Radius of gyration Rg (Guinier) rg_guinier	24.42 Å
Radius of gyration Rg (electron density) rg_electron	23.28 Å
Forward intensity I(0) i0	32382200.00
Molecular weight molecular_weight	44677.0 kDa
Excluded volume excluded_volume	56344 Å³
Envelope volume envelope_volume	68918 Å³
Hydration-shell volume shell_volume	24786 Å³
Envelope diameter envelope_diameter	88.5 Å
Shell Rg shell_rg	30.11 Å
Envelope Rg envelope_rg	23.69 Å
Shape Rg shape_rg	23.26 Å
Total Rg total_rg	24.17 Å
Total atoms total_atoms	3139
Residues n_residues	385
Spherical-harmonic order n_harmonics	20
q range q_range	— – 0.5000 Å⁻¹
Data points n_points	101
Shell type shell_type	directional
Solvent electron density solvent_density	0.3340 e/Å³
Shell contrast contrast_shell	0.0300 e/Å³
CRYSOL version crysol_version	4.1.3

▼

4. P(r) Distance Distribution (GNOM inversion) 4. P(r) Analysis (GNOM)

Maximum dimension Dmax dmax	85.8 Å
Rg (real space) rg_real	24.38 Å
Rg uncertainty (real space) rg_real_error	0.76 Å
I(0) (real space) i0_real	3.2380e+07
I(0) uncertainty (real space) i0_real_error	5.0250e+05
Rg (reciprocal space) rg_reciprocal	24.40 Å
I(0) (reciprocal space) i0_reciprocal	32380000.0000
Solution quality estimate total_estimate	0.8643
Solution quality rating solution_quality	GOOD a GOOD solution
P(r) peaks n_peaks	2
Primary peak position r_peak_primary	28.6 Å
Skewness Skewness skewness	0.322
Kurtosis Kurtosis kurtosis	-0.201
Angular range angular_range	— – 0.3250 Å⁻¹
Current regularization parameter α current_alpha	0.0000
Highest regularization parameter α highest_alpha	5296000.0000
Real-space data points n_real_points	64
GNOM version gnom_version	4.1.3
Quality Criteria quality_criteria	AN1: 0.000; Oscil: 0.767; Stabil: 1.000; Sysdev: 1.000; Positv: 1.000; Valcen: 0.943; Smooth: 0.989

▶

5. Crystallography and Experiment 5. Crystallography & Experiment

▶

6. Entities and Polymers Entities & Polymers (5)

Entity 1 Entity 1 polymer

Description description	Phosphatidylinositol 4-kinase beta
Molecular weight formula_weight	48403.6 kDa
EC 编号 ec_number	2.7.1.67
Mutation mutation	R409Q,R412Q
Source method src_method	man
Copy count entity_count	1

Polymer Polymer

Polymer type type	polypeptide(L)
Chain IDs strand_id	A
Atom count atom_count	3420

GRTASNPKVENEDEPVRLAPEREFIKSLMAIGKRLATLPTKEQKTQRLISELSLLNHKLPARVWLPTAGFDHHVVRVPHTQAVVLNSKDKAPYLIYVEVLECENFDTTSVPARIPENRIQSTQSVETAFKRDPEDPSAVALKEPWQEKVRRIREGSPYGHLPNWRLLSVIVKCGDDLRQELLAFQVLKQLQSIWEQERVPLWIKPYKILVISADSGMIEPVVNAVSIHQVKKQSQLSLLDYFLQEHGSYTTEAFLSAQRNFVQSCAGYCLVCYLLQVKDRHNGNILLDAEGHIIHIDFGFILSSSPRNLGFETSAFKLTTEFVDVMGGLDGDMFNYYKMLMLQGLIAARKHMDKVVQIVEIMQQGSQLPCFHGSSTIRNLKERFHMSMTEEQLQLLVEQMVDGSMRSITTKLYDGFQYLTNGIM

来源 Source

来源生物 organism	Homo sapiens
通用名 common_name	human
NCBI Class编号 ncbi_taxonomy_id	9606
宿主生物 host_organism	Baculovirus expression vector pFastBac1-HM

Entity 2 Entity 2 non-polymer

Description description	MAGNESIUM ION
Molecular weight formula_weight	24.3 kDa
Source method src_method	syn
Copy count entity_count	1

Entity 3 Entity 3 non-polymer

Description description	3-(3-fluorosulfonyloxy-4-methoxy-phenyl)-7-[(4-fluorosulfonyloxyphenyl)methylamino]-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine
Molecular weight formula_weight	554.5 kDa
Source method src_method	syn
Copy count entity_count	1

Entity 4 Entity 4 non-polymer

Description description	1,2-ETHANEDIOL
Molecular weight formula_weight	62.1 kDa
Source method src_method	syn
Copy count entity_count	1

Entity 5 Entity 5 water

Description description	water
Molecular weight formula_weight	18.0 kDa
Source method src_method	nat
Copy count entity_count	249

▶

8. Citations (1)

▶

Unit-cell length a length_a	58.839 Å
Unit-cell length b length_b	67.845 Å
Unit-cell length c length_c	107.033 Å
Unit-cell angle α angle_alpha	90.00 °
Unit-cell angle β angle_beta	90.00 °
Unit-cell angle γ angle_gamma	90.00 °
Molecules per unit cell Z z_pdb	4

Space group space_group	P 21 21 21
Space-group number int_tables_number	19
Crystal system crystal_system	—

Resolution resolution	1.940 Å
Low-resolution limit resolution_low	20.000 Å
R factor r_factor	0.1727
R_work r_work	0.1695
R_free r_free	0.2368

fit	/app/data/saxs_computation/q6/8q6h/8q6h.fit
pddf	/app/data/pr_computation/q6/8q6h/8q6h.pr.out
profile	/app/data/saxs_computation/q6/8q6h/8q6h.dat

HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 11)

1. Protein Identity and Related Structures Protein Identity & Related Structures

Phosphatidylinositol 4-kinase beta

State in the Current Structure

Other States of the Same Protein in the Database

Phosphatidylinositol 4-kinase beta

State in the Current Structure

Other States of the Same Protein in the Database

SAXS scattering curve SAXS Profile

P(r) Distance Distribution P(r) Distribution

2. Structure Basics 2. Structure Basics

3. SAXS Parameters (CRYSOL theoretical calculation) 3. SAXS Parameters (CRYSOL)

4. P(r) Distance Distribution (GNOM inversion) 4. P(r) Analysis (GNOM)

5. Crystallography and Experiment 5. Crystallography & Experiment

Unit cell Unit Cell

Symmetry Symmetry

Refinement Refinement

Diffraction experiment Diffraction

6. Entities and Polymers Entities & Polymers (5)

Entity 1 Entity 1 polymer

Polymer Polymer

来源 Source

Entity 2 Entity 2 non-polymer

Entity 3 Entity 3 non-polymer

Entity 4 Entity 4 non-polymer

Entity 5 Entity 5 water

8. Citations (1)

9. Files and Curves (10)

Files (7)

Curves (3)